Drug Profile
AGI 134
Alternative Names: AGI-134; Alpha-gal glycosphingolipids; Beta-galactosidase glycosphingolipid - BioLineRx; Glycosphingolipid beta-galactosidase immunotherapy; GSL-alpha-GALLatest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Agalimmune
- Developer BioLineRx
- Class Antineoplastics; Cancer vaccines; Glycolipids; Immunotherapies
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 Dec 2023 BioLineRx completes a phase I/IIa trial in Solid tumours (Inoperable/Unresectable, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA, Israel, and United Kingdom (Intratumoural) (NCT03593226) (EudraCT2018-001032-22)
- 20 Dec 2022 Efficacy and adverse events data from a phase-I/IIa clinical trials in Solid tumours released by BioLineRx
- 29 Sep 2022 9369440- No update